Guggenheim initiated coverage of Black Diamond Therapeutics (BDTX) with a Buy rating and $8 price target The firm believes the company’s silevertinib could surpass expectations with its second half of 2025 readout. Black Diamond has a “legitimate claim to have the most rationally designed” EGFR inhibitor for the “sizable” non-classical EGFRm non-small cell lung cancer population, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Black Diamond Therapeutics initiated with a Buy at Guggenheim
- Black Diamond price target lowered to $10 from $12 at H.C. Wainwright
- Black Diamond Therapeutics Reports Strong Financial Turnaround
- Black Diamond Therapeutics reports Q2 EPS (19c), consensus (23c)
- Black Diamond Therapeutics sees cash runway into 4Q27